Rznomics joined Lilly Gateway Labs in San Diego to accelerate discovery and development of RNA therapeutic candidates, the companies announced. The clinical-stage RNA platform company said it will collaborate with Lilly’s scientists and use the hub’s wet lab access to drive programs across a target database with more than 200 disease targets. Rznomics also aims to build long-term global clinical infrastructure, expand strategic partnerships, and recruit additional R&D talent in the U.S. Lilly Gateway Labs operates within Lilly Catalyze360, alongside multiple units that provide capital and R&D support. The move signals increased operational integration between RNA therapeutics developers and large pharma innovation hubs, with near-term emphasis on candidate advancement and infrastructure expansion.